Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II Study of Enfortumab Vedotin and Pembrolizumab Combined with Radiotherapy As a Bladder-Sparing Trimodality Therapy in Muscle Invasive Bladder Cancer

Next Previous
Trial Profile

Phase Ib/II Study of Enfortumab Vedotin and Pembrolizumab Combined with Radiotherapy As a Bladder-Sparing Trimodality Therapy in Muscle Invasive Bladder Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 01 Apr 2025 Status changed from completed to not yet recruiting.
  • 19 Mar 2025 Planned End Date changed from 30 Nov 2027 to 31 Jan 2028.
  • 19 Mar 2025 Planned primary completion date changed from 30 Nov 2027 to 31 Jan 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top